- Home
- CANG vs NLSP Comparison
CANG vs NLSP Comparison
Compare CANG & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANG
- NLSP
- Stock Information
- Founded
- CANG 2010
- NLSP 2015
- Country
- CANG China
- NLSP Switzerland
- Employees
- CANG N/A
- NLSP N/A
- Industry
- CANG Computer Software: Prepackaged Software
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- CANG Technology
- NLSP Health Care
- Exchange
- CANG Nasdaq
- NLSP Nasdaq
- Market Cap
- CANG 297.4M
- NLSP 243.8M
- IPO Year
- CANG 2018
- NLSP 2021
- Fundamental
- Price
- CANG $3.87
- NLSP $3.98
- Analyst Decision
- CANG
- NLSP
- Analyst Count
- CANG 0
- NLSP 0
- Target Price
- CANG N/A
- NLSP N/A
- AVG Volume (30 Days)
- CANG 144.6K
- NLSP 611.5K
- Earning Date
- CANG 11-04-2024
- NLSP 11-15-2024
- Dividend Yield
- CANG N/A
- NLSP N/A
- EPS Growth
- CANG N/A
- NLSP N/A
- EPS
- CANG 0.17
- NLSP N/A
- Revenue
- CANG $38,020,222.00
- NLSP N/A
- Revenue This Year
- CANG $253.48
- NLSP N/A
- Revenue Next Year
- CANG N/A
- NLSP N/A
- P/E Ratio
- CANG $15.99
- NLSP N/A
- Revenue Growth
- CANG N/A
- NLSP N/A
- 52 Week Low
- CANG $0.92
- NLSP $3.51
- 52 Week High
- CANG $3.00
- NLSP $29.08
- Technical
- Relative Strength Index (RSI)
- CANG 76.60
- NLSP 41.77
- Support Level
- CANG $2.50
- NLSP $3.56
- Resistance Level
- CANG $3.00
- NLSP $4.34
- Average True Range (ATR)
- CANG 0.24
- NLSP 0.45
- MACD
- CANG 0.08
- NLSP 0.03
- Stochastic Oscillator
- CANG 95.40
- NLSP 31.19
About CANG Cango Inc. each representing two (2)
Cango Inc is an automotive transaction service platform in China connecting dealers, financial institutions, car buyers, and other industry participants. The services mainly consist of - automotive financing facilitation, automotive transaction facilitation, and aftermarket service facilitation. Geographically, it derives revenue from China.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.